Newsbenzinga
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
· Published
Article summary
Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.
An excerpt from the original article.
Comments —
Loading comments…